Traitement en cours

Veuillez attendre...

PATENTSCOPE sera indisponible durant quelques heures pour des raisons de maintenance le mardi 25.01.2022 à 12:00 PM CET
Paramétrages

Paramétrages

Aller à Demande

1. CA3128498 - PROCEDES DE TRAITEMENT PROPHYLACTIQUE UTILISANT VWF RECOMBINANT (RVWF)

Office
Canada
Numéro de la demande 3128498
Date de la demande
Numéro de publication 3128498
Date de publication 06.08.2020
Type de publication A1
CIB
A61K 38/36
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
38Préparations médicinales contenant des peptides
16Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
17provenant d'animaux; provenant d'humains
36Facteurs de coagulation sanguine ou de fibrinolyse
A61K 38/37
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
38Préparations médicinales contenant des peptides
16Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
17provenant d'animaux; provenant d'humains
36Facteurs de coagulation sanguine ou de fibrinolyse
37Facteurs VIII
A61P 7/04
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
PACTIVITÉ THÉRAPEUTIQUE SPÉCIFIQUE DE COMPOSÉS CHIMIQUES OU DE PRÉPARATIONS MÉDICINALES
7Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
04Antihémorragiques; Profacteurs de coagulation; Agents hémostatiques; Agents antifibrinolytiques
C07K 14/745
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
14Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
435provenant d'animaux; provenant d'humains
745Facteurs de coagulation sanguine ou de fibrinolyse
C07K 14/755
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
14Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
435provenant d'animaux; provenant d'humains
745Facteurs de coagulation sanguine ou de fibrinolyse
755Facteurs VIII
CPC
A61K 38/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
36Blood coagulation or fibrinolysis factors
A61K 38/37
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
36Blood coagulation or fibrinolysis factors
37Factors VIII
A61P 7/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
04Antihaemorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents
C07K 14/755
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
745Blood coagulation or fibrinolysis factors
755Factors VIII ; , e.g. factor VIII C (AHF), factor VIII Ag (VWF)
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
G01N 33/86
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
86involving blood coagulating time ; or factors, or their receptors
Déposants BAXALTA GMBH
BAXALTA INCORPORATED
Données relatives à la priorité 62/800,370 01.02.2019 US
Titre
(EN) METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (RVWF)
(FR) PROCEDES DE TRAITEMENT PROPHYLACTIQUE UTILISANT VWF RECOMBINANT (RVWF)
Abrégé
(EN) The present invention relates to a method for prophylactic treatment of spontaneous bleeding in a subject with severe von Willebrand Disease comprising administering a therapeutic amount of recombinant von Willebrand Factor (rVWF) to the subject.


Related patent documents
MXMX/a/2021/009114This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
JP2021544509This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
UAa202104447This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.